Taurine

Research records

Historical source snapshot. Not freshly verified, not a recommendation. Study findings, community accounts and app defaults are not interchangeable.

Publication suitability · 2026-10-15: Historical reference only; not a clinical verification. Clinical, regulatory, efficacy, safety and dose claims are not independently established by this review.

Taurine

Conditionally essential amino acid studied for cardiovascular and exercise outcomes.

Evidence category: Systematic review. This describes the source category, not approval or certainty.

Regulatory statement in source: Not separately recorded; do not infer approval from the evidence category.

Taurine is an amino acid present in food and sold as a supplement. A systematic review of human studies in dilated cardiomyopathy and heart failure found reported improvements but concluded the evidence base is small and of mixed quality. A small double-blind heart-failure trial that reported benefits has since been retracted, so it is not cited here. An older review describes possible cardiovascular effects and says long-term double-blind trials are still needed. Human evidence is limited and the studies are small.

Benefits reported in the imported source

• Individual studies in heart failure reported higher ejection fraction and smaller left ventricular volumes

Risks and limits

• Pooled ejection fraction and stroke volume showed no significant effect
• The human evidence base is small and of mixed quality, and one supportive trial was retracted
• Reviewers say long-term double-blind trials are still needed

Source bottom line: Taurine's heart-failure evidence is small and mixed, with no significant pooled effect on heart function.

Uncertainty: Reference information only. Not medical advice.

Study protocols — reports, not instructions

Community and practice descriptions

Accounts of a practice are not evidence of safety or effectiveness. Words such as “standard”, “safe” or “recommended” describe the source account, not verified consensus or this wiki’s advice. Commercial and self-published citations are retained for traceability, not vendor endorsement or independent clinical corroboration.

Pharmacokinetic context

Historical half-life estimate: 1 hours. Ghandforoush-Sattari et al. 2010, J Amino Acids, PMID 22331937 — oral 4g dose, healthy adults; rapid clearance reflects efficient renal handling and tissue uptake, not first-order elimination in the pharmacokinetic sense Population/route context and estimates may differ. This is not a schedule or a verified human dosing rule.

Source references

• Effect of taurine administration on symptoms, severity, or clinical outcome of dilated cardiomyopathy and heart failure in humans: a systematic review (availability check 2026-10-15: possible access barrier; not independently inspected; HTTP 200)
• The potential health benefits of taurine in cardiovascular disease (Xu et al. 2008)
• PubMed: taurine supplementation